| Literature DB >> 33778704 |
W Tania Rahman1, Colleen H Neal1, Alexis Virginia Nees1, Richard K J Brown1.
Abstract
Nuclear medicine studies are often performed in patients with breast cancer; however, incidental radiotracer uptake in the breasts can be observed in patients with nonbreast malignancies. Benign and malignant lesions can be identified on planar, SPECT, and PET scans. This review will outline the molecular and radiographic imaging appearance of benign and malignant breast lesions on sestamibi scans, bone scans, radioiodine studies, as well as PET studies using fluorine 18 (18F) fluorodeoxyglucose, gallium 68 (68Ga) tetraazacyclododecane tetraacetic acid octreotate (or DOTATATE), 68Ga prostate-specific membrane antigen, and 18F-fluciclovine radiotracers. Recognizing these lesions at molecular and anatomic imaging is important to ensure accurate diagnosis and appropriate management. Keywords: Breast, Mammography, Molecular Imaging, PET/CT, Radionuclide Studies, SPECT/CT © RSNA, 2020. 2020 by the Radiological Society of North America, Inc.Entities:
Year: 2020 PMID: 33778704 PMCID: PMC7983741 DOI: 10.1148/rycan.2020190037
Source DB: PubMed Journal: Radiol Imaging Cancer ISSN: 2638-616X